At the Crossroad of Care: New Advances in Diabetic Kidney Disease

Friday, January 29, 2021, 8:00 AM - Friday, January 28, 2022, 11:59 PM


AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Type 2 diabetes mellitus (T2DM) represents the main cause of chronic kidney disease and end-stage renal disease, accounting for almost 50 percent of all patients starting renal replacement therapy worldwide. At least half of the patients with T2DM will develop diabetic kidney disease (DKD). DKD is the single strongest predictor of morbidity and premature mortality in patients with diabetes. Even mild increases in albuminuria or GFR decline are associated with an increased risk of cardiovascular diseases and CV death, along with increased health-care costs. Therefore, kidney protection is a critical target in T2DM. Join us as we take a look at new therapeutic agents for the prevention of DKD development and progression.

1. Develop a framework for evaluation of glycemic control to delay or prevent the onset and progression of DKD;
2. Assess the clinical data of newer and emerging treatments providing reno-cardiovascular protection for patients with DKD;
3. Recognize the management of DKD necessitates a multifactorial approach, beyond medical therapy, that includes fostering an effective patient-provider relationship to optimize outcomes.

There are no fees for participating in and receiving CME credit for this online activity.

To participate in this activity, register with ReachMD.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CORE Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CME FRONT MATTER

Faculty & Disclosure / Conflict of Interest Policy
According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose all ineligible company relationships within the last 24 months. All educational materials are reviewed and mitigated for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Medical Director & Program Planners

CORE Medical Education, LLC
Otto Ratz, MD
Christina Culbert, MSc

CORE Medical Education staff have no relevant conflict of interest to report.

University of Cincinnati Continuing Medical Education Office
Bruce Gebhardt, MD, Professor, Physician Reviewer
Susan P. Tyler, PhD, MEd, CMP, CHCP, Director
Heather Muskopf, Program Manager

University of Cincinnati staff have no relevant conflict of interest to report.

Disclaimer Statement
The opinions expressed during the endured activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Neither the University of Cincinnati College of Medicine nor CORE Medical Education, LLC, recommends the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati College of Medicine or CORE Medical Education, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members’ relationships with drug or device manufacturer(s). The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Off-Label Disclosure Statement
Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

 

This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.